Data and Supplementary Materials for KRAS, BRCA, and TP53 Mutations as Prognostic Biomarkers in Pancreatic Cancer: A Systematic Review and Meta-Analysis

Abstract

KRAS, BRCA, and TP53 Mutations as Prognostic Biomarkers in Pancreatic Cancer: A Systematic Review and Meta-Analysis1. General InformationStudy Title: KRAS, BRCA, and TP53 Mutations as Prognostic Biomarkers in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Survival OutcomesCorresponding Author: Wahby Mohammed BabareshAffiliation: Faculty of Pharmacy, University of Aden, Aden, YemenEmail: wahbi.mohammed.pharm@aden-univ.net/ ORCID iD: 0009-0009-2325-9609PROSPERO Protocol Registration: CRD4202614304552. File OverviewThis repository contains the curated extraction dataset and supplementary search strategy documentation supporting the systematic review and meta-analysis:Pancreatic cancer data.xlsx`Master data extraction workbook containing baseline study characteristics, pooled effect estimates, and outcome/mutation subsets.Supplementary_Materials.docx`Comprehensive electronic database search strings (PubMed, Cochrane Library, Embase), supplementary leave-one-out sensitivity plots (DL and REML models), funnel plots, trim-and-fill analysis, and publication bias asymmetry tests (Egger's regression and Begg's rank correlation).3. Data Structure (`pancreatic cancer data.xlsx`)The workbook consists of 10 individual sheets formatted as follows:characteristics table`: Baseline characteristics of the 20 included studies (Study citation, Country, Study Design, Setting, Duration, Sample size [Mutation-positive/wild-type], Patient Age, Gender ratio).mdata`: Comprehensive master data extraction sheet containing all identified cohort comparisons, mutation profiles, detection platforms, and reported survival metrics.OS`: Studies and cohorts reporting Overall Survival endpoints with corresponding effect estimates (HR and 95% CI).PFS`: Studies and cohorts reporting Progression-Free Survival endpoints.DFS`: Studies and cohorts reporting Disease-Free Survival endpoints.KRAS, OS`: Subgroup extraction dataset for KRAS mutations evaluated against Overall Survival.p53, OS`: Subgroup extraction dataset for TP53/p53 mutations evaluated against Overall Survival.BRCA, OS`: Subgroup extraction dataset for BRCA1/BRCA2 mutations evaluated against Overall Survival.BRCA, PFS`: Subgroup extraction dataset for BRCA mutations evaluated against Progression-Free Survival.KRAS, PFS`: Subgroup extraction dataset for KRAS mutations evaluated against Progression-Free Survival.4. Methodological Summary & Software EnvironmentStudy Screening & Quality Assessment: Literature screening conducted per PRISMA 2020 guidelines; study quality and risk of bias evaluated via the Quality in Prognosis Studies (QUIPS) framework across 6 key domains.Meta-Analytic Synthesis: Conducted in R/RStudio (version 4.3.0) utilizing random-effects models (DerSimonian–Laird and Restricted Maximum Likelihood [REML] estimators) implemented primarily through the `meta` and `metafor` packages.Effect Metrics: Natural log hazard ratios [ln(HR)] and standard errors [SE(lnHR)] derived from published Cox models, Kaplan–Meier survival curves, or summary survival statistics.5. Terms of Use & CitationThis open-access dataset is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Users are free to share and adapt the material, provided appropriate academic credit is cited according to the published manuscript.